Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen dsat - Stratatech

Next Previous
Drug Profile

Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen dsat - Stratatech

Alternative Names: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen- dsat; Human skin replacement - Stratatech; SOMA Tx - Stratatech; StrataGraft; StrataGraft Overlay of Meshed Autograft - Stratatech

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Wisconsin System; Wisconsin Alumni Research Foundation
  • Developer Stratatech
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Burns
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Burns
  • Discontinued Wounds

Most Recent Events

  • 04 Jan 2024 Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen dsat is available for licensing as of 04 Jan 2024. https://www.mallinckrodt.com/contact-us/
  • 05 Sep 2023 Mallinckrodt receives US FDA label update for StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) to reduce xenotransplantation requirements
  • 30 Dec 2022 Mallinckrodt Pharmaceuticals has patent protection for StrataGraft® in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top